Elanco Animal Health (NYSE:ELAN) Issues FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.910-0.940 for the period, compared to the consensus EPS estimate of 0.900. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $4.6 billion. Elanco Animal Health also updated its Q4 2025 guidance to 0.090-0.120 EPS.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELAN. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday. UBS Group raised their price target on Elanco Animal Health from $19.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 20th. Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a report on Thursday, July 17th. Stifel Nicolaus raised their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Finally, Piper Sandler raised their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $22.58 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The firm has a market cap of $11.22 billion, a P/E ratio of 26.25, a P/E/G ratio of 3.56 and a beta of 1.71. The firm has a 50 day simple moving average of $19.98 and a 200 day simple moving average of $16.00. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $22.95.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the previous year, the business earned $0.30 EPS. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Sell-side analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ELAN. Goldman Sachs Group Inc. boosted its position in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Holocene Advisors LP boosted its position in shares of Elanco Animal Health by 29.1% in the 2nd quarter. Holocene Advisors LP now owns 2,886,294 shares of the company’s stock worth $41,216,000 after purchasing an additional 649,820 shares during the last quarter. Quantinno Capital Management LP boosted its position in shares of Elanco Animal Health by 308.8% in the 2nd quarter. Quantinno Capital Management LP now owns 784,752 shares of the company’s stock worth $11,206,000 after purchasing an additional 592,788 shares during the last quarter. Balyasny Asset Management L.P. boosted its position in shares of Elanco Animal Health by 32.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 2,309,886 shares of the company’s stock worth $32,985,000 after purchasing an additional 571,444 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Elanco Animal Health by 29.7% in the 2nd quarter. Bank of America Corp DE now owns 2,139,892 shares of the company’s stock worth $30,558,000 after purchasing an additional 489,659 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.